1
|
Takaya K, Baba M, Kuranami M, Shido H, Asou T, Kishi K. Usefulness of Harmonic ACE+7 Scalpel in Breast Reconstruction with Extended Latissimus Dorsi Flap: An Open-label Single Institution Pilot Study. Plast Reconstr Surg Glob Open 2023; 11:e5163. [PMID: 37547349 PMCID: PMC10400065 DOI: 10.1097/gox.0000000000005163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 06/14/2023] [Indexed: 08/08/2023]
Abstract
The extended latissimus dorsi (ELD) flap is a safe and aesthetically acceptable method to reconstruct small to medium-sized breasts. However, the long time required for flap elevation and intraoperative bleeding contributes to various postoperative complications. We investigated the use of alternative devices, such as the Harmonic ACE+7, which has a long arm that can help simultaneously detach and seal tissues to prevent such complications. Methods We compared 27 patients who underwent breast reconstruction with the ELD flap using the Harmonic ACE +7 scalpel, and 28 patients who underwent breast reconstruction using an electrocautery scalpel, between May 2019 and March 2022. Data on patient demographics, surgery, and postoperative complications were collected. Surgical outcomes were compared between electrocautery (EC) and Harmonic ACE+7 (HA) groups. Results The median age of the patients was 50.2 years. The patient demographics between the groups did not show significant differences. Flap necrosis and hematomas did not occur, and seroma was the major postoperative complication (65.7% in the EC group and 70% in the HA group). The time required for flap elevation was significantly shorter in the HA group than in the EC group (286.0 minutes and 179.0 minutes, respectively). Blood loss reduced significantly in the HA and EC groups (138.5 mL and 78.2 mL, respectively). Moreover, decreased drainage was observed for the breast area. There were no significant differences in other end points. Conclusion In breast reconstruction with ELD flaps, using the Harmonic ACE+7 can help reduce the rate of seroma, operative time, and intraoperative bleeding without further disadvantages.
Collapse
Affiliation(s)
- Kento Takaya
- From the Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo, Japan
- Yamato Municipal Hospital, Kanagawa, Japan
| | - Miho Baba
- From the Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo, Japan
| | | | | | - Toru Asou
- From the Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo, Japan
| | - Kazuo Kishi
- From the Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
2
|
Narui K, Ishikawa T, Shimizu D, Yamada A, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Niikura N, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. Breast 2019; 47:1-9. [DOI: 10.1016/j.breast.2019.06.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2019] [Revised: 05/25/2019] [Accepted: 06/10/2019] [Indexed: 01/16/2023] Open
|
3
|
Narui K, Ishikawa T, Shimizu D, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Abstract P5-16-04: A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: This study aimed to evaluate response to neoadjuvant chemotherapy (NAC) for patients with hormone receptor-negative (HR-negative) breast cancer (BC) to identify subtypes that require anthracycline treatment.
Methods: In total, 103 patients with operable HR-negative BC were registered. They were randomely assigned to administration of 6 cycles of docetaxel (75mg/m2) and cyclophosphamide (600 mg/m2) (TC6) or 3 cycles of 5-fluorouracil (500 mg/m2), epirubicin (100mg/m2), and cyclophosphamide (500mg/m2) followed by 3 cycles of docetaxel (100mg/m2) (FEC-D). Cytokeratin (CK) 5/6 and EGFR expression were used to identify basal and non-basal triple-negative (TN) BC. The primary endpoint was pathological complete response (pCR); secondary endpoints were safety, breast-conserving surgery, disease-free survival, and overall survival. Predictive factors of pCR for each regimen were also evaluated.
Results:
The pCR rate was 36% for FEC-D and 25.5% for TC6, which did not differ significantly (P=0.265). When TN BC was subdivided into basal and non-basal subtypes, the pCR rate in the basal subtype was significantly lower for TC6 (13.6%) than for FEC-D (42.9%) (P=0.033), but did not significantly differ in the non-basal (TC6, 36.4%; FEC-D, 25.0%) and HER2-positive (TC6, 41.7%; FEC-D, 35.7%) cases.
The relative dose intensities of epirubicin and docetaxel in FEC-D and docetaxel in TC6 were 96.3±13.0%, 93.5±14.6%, and 93.9±16.3% (mean±SD), respectively. Occurrence of grade ≥2 adverse events was significant in FEC-D-treated patients. Poor appetite (P<0.001), nausea (P<0.001), vomiting (P<0.001), dysgeusia (P=0.03), and fatigue (P=0.05) were significantly more common for FEC-D than TC6. Patients treated with FEC-D experienced significantly more febrile neutropenia and anemia (P=0.016 and 0.017, respectively).
The rates of breast-conserving surgery were 68.0 and 72.3% for FEC-D and TC6, respectively (P=0.641).
Patients achieved pCR had better DFS (log rank test, P = 0.287) and OS (log rank test, P = 0.069), though not significant. Patients treated with FEC-D had better DFS (log rank test, P = 0.107) and OS (log rank test, P = 0.159), though not significant. Among patients with TN BC, those treated with FEC-D had significantly better DFS (log rank test, P = 0.016) and OS (log rank test, P = 0.034) than treated with TC6.
Low ALDH1 expression and high topo IIα protein expression were strongly correlated with pCR in FEC-D, with odds ratios (ORs) of 4.33 [95% CI, 1.02–18.38] and 4.08 [0.97–17.2], respectively. ALDH1 was also associated with pCR in TC, OR=3.50 [0.84–14.6]. Other factors, including age, tumor size, nodal status, tumor grade, Ki67, p53, and TOP 2A status were not associated with pCR in either regimen.
Conclusions:We found that TC6 was less effective than FEC-D for treating HR-negative BC because it was insufficient for TNBC, particularly for basal BC. This suggests that anthracycline is more important than taxane for basal BC. Additionally, ALDH1 could be a marker for resistance to conventional chemotherapy.
Citation Format: Narui K, Ishikawa T, Shimizu D, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-04.
Collapse
Affiliation(s)
- K Narui
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Ishikawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - D Shimizu
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Tanabe
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Sasaki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - MS Oba
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - S Morita
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - S Nawata
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - K Kida
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Mogaki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Doi
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - K Tsugawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - H Ogata
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Ota
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Kosaka
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - N Sengoku
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Kuranami
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Saito
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Suzuki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - A Suto
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - H Arioka
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Chishima
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Ichikawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - I Endo
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Tokuda
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| |
Collapse
|
4
|
Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata H, Mukai H, Uemura Y, Ohashi Y. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer 2017; 123:759-768. [PMID: 28081304 PMCID: PMC6668007 DOI: 10.1002/cncr.30421] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 09/20/2016] [Accepted: 10/03/2016] [Indexed: 11/09/2022]
Abstract
BACKGROUND In postoperative patients with breast cancer, the combination of an anthracycline and cyclophosphamide (AC) followed by a taxane is a standard regimen. In the current study, the authors examined whether AC could be safely omitted, and compared the effectiveness of paclitaxel versus docetaxel. METHODS Female postoperative patients with axillary lymph node‐positive breast cancer were eligible for enrollment in this phase 3, open‐label, randomized controlled trial at 84 centers in Japan. Patients were randomized to 4 cycles of doxorubicin at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 (AC) followed by 4 cycles of paclitaxel at a dose of 175 mg/m2 (ACpT) or AC followed by 4 cycles of docetaxel at a dose of 75 mg/m2 (ACdT), or 8 cycles of paclitaxel (PTx) or docetaxel (DTx) every 3 weeks. The primary endpoint was disease‐free survival (DFS). Secondary endpoints included overall survival adverse events. The authors adopted a 2 × 2 factorial design to examine the AC containing‐regimens (ACpT and ACdT) versus the AC free‐regimens (PTx and DTx), and the paclitaxel‐containing regimens (ACpT and PTx) versus the docetaxel‐containing regimens (ACdT and DTx). RESULTS Of 1060 patients, 1049 were treated and included in the intention‐to‐treat population. The DFS results did not demonstrate noninferiority between the AC‐containing and the AC‐free regimens (hazard ratio [HR], 1.19; 95% confidence interval [95% CI], 0.982‐1.448 [Pnoninferiority = .30]). Better outcomes were noted in patients treated with the docetaxel‐containing regimens compared with the paclitaxel‐containing regimens with respect to DFS (HR, 0.72; 95% CI, 0.589‐0.875 [P = .0008]) and overall survival (HR, 0.75; 95% CI, 0.574‐0.980 [P = .035]). Neutropenia, nausea, and vomiting were found to occur more often in the AC‐containing arms, whereas the incidence of edema was greater in the docetaxel‐containing treatment arms. CONCLUSIONS Noninferiority in DFS was not demonstrated between the AC‐containing and AC‐free regimens. Compared with a similar regimen of paclitaxel, docetaxel appeared to increase the DFS. Cancer 2017;123:759–68. © 2016 American Cancer Society. In postoperative patients with breast cancer, the combination of an anthracycline and cyclophosphamide followed by a taxane is a standard regimen. The results of the current phase 3 study demonstrate that noninferiority in disease‐free survival is not shown between regimens containing the combination of doxorubicin plus cyclophosphamide and those that do not, and that compared with a similar regimen of paclitaxel, docetaxel increased disease‐free survival.
Collapse
Affiliation(s)
- Toru Watanabe
- Department of Medical Oncology, Hamamatsu Oncology Center, Hamamatsu, Japan
| | - Masaru Kuranami
- Department of Surgery, Yamato Municipal Hospital, Yamato, Japan
| | - Kenichi Inoue
- Breast Oncology, Saitama Cancer Center, Kita-Adachi, Japan
| | - Norikazu Masuda
- Division of Breast Surgery, Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - Kenjiro Aogi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Shinji Ohno
- Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation of Cancer Research, Tokyo, Japan
| | - Hiroji Iwata
- Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Hirofumi Mukai
- Department of Oncology and Hematology, National Cancer Center Hospital East, Kashiwa, Japan
| | - Yukari Uemura
- Clinical Research Support Center (CresCent), The University of Tokyo Hospital, Tokyo, Japan
| | - Yasuo Ohashi
- Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Tokyo, Japan
| |
Collapse
|
5
|
Sengoku N, Tanino H, Kosaka Y, Kikuchi M, Nishimiya H, Waraya M, Katoh H, Enomoto T, Sato T, Kuranami M, Watanabe M. The safety of concentrated trastuzumab in 100 ml of saline solution for administration to patients with HER2-positive breast cancer: a phase 1 study. Chemotherapy 2014; 60:1-6. [PMID: 25301171 DOI: 10.1159/000365723] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Accepted: 07/03/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND It is recommended that administration of trastuzumab should be carried out in a volume of 250 ml of saline solution over 90 min. Since 2011, recommendations have allowed a shortening of the administration time to 30 min at the second administration. However, the volume to be administered is still 250 ml. The purpose of this study was to evaluate the safety of trastuzumab administered in 100 ml of saline solution over 30 min. METHODS This study enrolled patients with HER2-positive breast cancer. Three dose levels of trastuzumab, each in 100 ml of saline solution, were used (2, 6 and 8 mg/kg). The primary end point was the determination of safety. RESULTS Nine patients were enrolled. Since no adverse events were observed, the 8 mg/kg/100 ml saline solution dose level was the recommended dose. CONCLUSIONS A 30-min administration of trastuzumab in 100 ml of saline solution is safe in patients with HER2-positive breast cancer.
Collapse
Affiliation(s)
- Norihiko Sengoku
- Department of Surgery, Kitasato University School of Medicine, Sagamihara, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Nakatani Y, Iwamitsu Y, Kuranami M, Okazaki S, Shikanai H, Yamamoto K, Watanabe M, Miyaoka H. The relationship between emotional suppression and psychological distress in breast cancer patients after surgery. Jpn J Clin Oncol 2014; 44:818-25. [PMID: 25028697 DOI: 10.1093/jjco/hyu089] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVE The purpose of this study was to examine the relationship between emotional suppression and psychological distress in breast cancer patients after surgery. We examined this relationship using questionnaires at the first visit to the breast cancer outpatient clinic at our hospital and after surgery, as well as interviews after surgery. METHODS A total of 31 breast cancer patients were asked to complete the Courtauld Emotional Control Scale and the Profile of Mood States at their first visit to the outpatient clinic. Patients were also asked to complete the Profile of Mood States between 1 and 6 months after surgery. Trained clinical psychologists conducted the interviews, asking patients to speak freely about their current anxieties, worries and thoughts. Based on the median Courtauld Emotional Control Scale score of 42 points, participants were divided into emotional suppression and emotional expression groups. RESULTS The Total Mood Disturbance score, as well as each of the subscale (except vigor) scores of the Profile of Mood States, were significantly higher in the emotional suppression group than the emotional expression group. The emotional suppression group expressed significantly more negative emotions and fewer positive emotions than the emotional expression group. CONCLUSIONS Patients with emotional suppression felt and expressed more psychological distress after surgery. This finding highlights the need for medical staff to comprehend the psychological traits of breast cancer patients, including emotional suppression, in the early stages of breast cancer in order to provide adequate psychological support.
Collapse
Affiliation(s)
- Yuki Nakatani
- Department of Medical Psychology, Kitasato University, Graduate School of Medical Sciences, Sagamihara
| | - Yumi Iwamitsu
- Department of Medical Psychology, Kitasato University, Graduate School of Medical Sciences, Sagamihara
| | | | - Shigemi Okazaki
- Department of Medical Psychology, Kitasato University, Graduate School of Medical Sciences, Sagamihara Higashiyamato General Hospital, Higashiyamato
| | - Hiroe Shikanai
- Department of Medical Psychology, Kitasato University, Graduate School of Medical Sciences, Sagamihara
| | - Kenji Yamamoto
- Department of Psychiatry, Tokai University, School of Medicine, Isehara
| | - Masahiko Watanabe
- Department of Surgery, Kitasato University, School of Medicine, Sagamihara
| | - Hitoshi Miyaoka
- Department of Psychiatry, Kitasato University, School of Medicine, Sagamihara, Japan
| |
Collapse
|
7
|
Nishimiya H, Kosaka Y, Yamashita K, Minatani N, Kikuchi M, Ema A, Nakamura K, Waraya M, Sengoku N, Tanino H, Kuranami M, Watanabe M. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up. Anticancer Res 2014; 34:259-268. [PMID: 24403472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND/AIM In order to define accurate survival outcome in breast cancer, 10-year follow-up is required and such long-term survival information are few and difficult to gather. PATIENTS AND METHODS We recruited 253 breast cancer patients who undertook operation with no prior chemotherapy. Ten-year survival outcomes were evaluated by clinicopathological factors. RESULTS Significant univariate prognostic factors were: T factor, N factor, preoperative values of tumor markers, and biological factors. T-factor, CEA, hormone receptor, and Ki-67 were the final independent prognostic factors of recurrence-free survival through multivariate analysis. The Luminal A group except for the Ki-67-positive cases showed the best survival outcomes, while the HER2-positive or triple-negative (TN) groups showed worse prognosis than the Luminal A group, and Ki-67 was shown to be an excellent prognostic factor in each stage (p<0.01). CONCLUSION Ki-67 has a great potential as a prognostic biomarker while prognostic information of this sort could be beneficial for development of novel therapeutic strategies.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/metabolism
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Lobular/mortality
- Carcinoma, Lobular/pathology
- Carcinoma, Lobular/surgery
- Female
- Follow-Up Studies
- Humans
- Immunoenzyme Techniques
- Ki-67 Antigen/metabolism
- Lymphatic Metastasis
- Male
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Recurrence, Local/mortality
- Neoplasm Recurrence, Local/pathology
- Neoplasm Recurrence, Local/surgery
- Neoplasm Staging
- Postoperative Complications
- Prognosis
- Receptor, ErbB-2/metabolism
- Receptors, Estrogen/metabolism
- Receptors, Progesterone/metabolism
- Survival Rate
- Time Factors
- Young Adult
Collapse
Affiliation(s)
- Hiroshi Nishimiya
- FACS, Department of Surgery, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Kosaka Y, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, Waraya M, Enomoto T, Kuranami M, Tanino H, Watanabe M. Abstract P3-09-03: Final result of randomised controlled phase II study of the efficiency of palonosetron, aprepitant, and dexamethasone for day1 with or without dexamethasone on days2 and 3. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-09-03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Emesis is one of the major non-hematologic toxicity caused by chemotherapy. The control of Chemotherapy Induced Nausea and Vomiting (CINV) is conducted to a life lengthening. Recently, CINV is controlled by the second generation 5-HT3 receptor blocker (Palonosetron; PALO) and a NK-1 receptor antagonist (Aprepitant; APR). It has been shown that dexamethasone (DEX) with 5-HT3 receptor blocker improves acute / delayed CINV. However, it has not been determined the medication schedule for DEX with PALO and APR. The purpose of this study is evaluated the efficiency of palonosetron, aprepitant and dexamethasone for day1 with or without dexamethasone on days2 and 3. This is final result of current study.
Methods: Breast cancer patients who administered anthracyclin drug regimen have been eligible from April, 2011 to June, 2013. The patients were randomised to group A (PALO/APR/DEX one day) and group B (PALO/APR/DEX three days).
Trial designAprepitant125mg80mg80mg Palonosetron0.75mg dexamethasone9.9mg6.6 mg or placebo6.6 mg or placebo Chemotherapydo days12345
Eighty patients were estimate as study samples. The primary endpoint was a complete response (CR) rate of vomiting, the secondary endpoint was a complete control (CC) rate of vomiting.
Results: Eighty two patients were enrolled in this study. There was not inferiority about CR rate of five days after chemotherapy (81.1% of group A, 82.1% of group B). CC rate of group A (62.2%) was better than that of group B (46.2%). However, CC rate was no significant difference between group A and B. There was no significant difference about any level of nausea between group A and B.
Conclusions: One day of dexamethasone with Palonosetron and Aprepitant treatment is enough to control the emesis of high emetogenic chemotherapeutic agents.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-09-03.
Collapse
Affiliation(s)
- Y Kosaka
- Kitasato University School of Medicine, Sagamihara, Japan
| | - N Sengoku
- Kitasato University School of Medicine, Sagamihara, Japan
| | - N Minatani
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kikuchi
- Kitasato University School of Medicine, Sagamihara, Japan
| | - H Nishimiya
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Waraya
- Kitasato University School of Medicine, Sagamihara, Japan
| | - T Enomoto
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kuranami
- Kitasato University School of Medicine, Sagamihara, Japan
| | - H Tanino
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Watanabe
- Kitasato University School of Medicine, Sagamihara, Japan
| |
Collapse
|
9
|
Rai Y, Sagara Y, Kuranami M, Masuda N, Takano T, Saeki T, Nakamura S, Ito Y, Tokuda Y, Tamura K. A Multicenter Randomized Phase III Study of KRN125 (Pegfilgrastim) in Breast Cancer Patients Receiving TC Chemotherapy. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt442.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
10
|
Kuranami M. [11. Breast treatment (1) surgical treatment and chemotherapy: now and future]. Nihon Hoshasen Gijutsu Gakkai Zasshi 2013; 69:303-14. [PMID: 23514860 DOI: 10.6009/jjrt.2013_jsrt_69.3.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
11
|
Kosaka Y, Sengoku N, Kikuchi M, Nishimiya H, Enomoto T, Kuranami M, Watanabe M. Abstract P2-12-13: Results of randomised controlled phase II study (KBCSG02 trial) of the efficiency of palonosetron, aprepitant, and dexamethasone for day1 with or without dexamethasone on days2 and 3. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-12-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Emesis is one of the major non-hematologic toxicity caused by chemotherapy. The control of Chemotherapy Induced Nausea and Vomiting (CINV) is conducted to a life lengthening. Recently, CINV is controlled by the second generation 5-HT3 receptor blocker (Palonosetron; PALO) and a NK-1 receptor antagonist (Aprepitant; APR). It has been shown that dexamethasone (DEX) with 5-HT3 receptor blocker improves acute/delayed CINV. However, it has not been determined the medication schedule of DEX with PALO and APR. The purpose of this study is evaluated the efficiency of palonosetron, aprepitant and dexamethasone for day1 with or without dexamethasone on days2 and 3.
Methods: Breast cancer patients who administered anthracyclin drug regimen have been eligible from April, 2011 to June, 2012. The patients were randomised to group A (PALO/APR/DEX one day) and group B (PALO/APR/DEX three days). Eighty patients was estimate as study samples. The primary endpoint was a complete response (CR) rate of vomiting, the secondary endpoint was a complete control (CC) rate of vomiting.
Results: Forty patients were enrolled in this study, and patient recruitment is continued. CR rate was no significant difference in both groups (76.9% of group A, 73.3% of group B). CC rate of group A (61.5%) did not show inferiority compared with group B (40.0%).
Conclusions: In this current study, we suggest that one day dexamethasone treatment could reduce enough the emesis of high emetogenic chemotherapeutic agents.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-12-13.
Collapse
Affiliation(s)
- Y Kosaka
- Kitasato University School of Medicine, Sagamihara, Japan
| | - N Sengoku
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kikuchi
- Kitasato University School of Medicine, Sagamihara, Japan
| | - H Nishimiya
- Kitasato University School of Medicine, Sagamihara, Japan
| | - T Enomoto
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kuranami
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Watanabe
- Kitasato University School of Medicine, Sagamihara, Japan
| |
Collapse
|
12
|
Waraya M, Kosaka Y, Sengoku N, Kikuchi M, Nishimiya H, Enomoto T, Kuranami M, Watanabe M. [Efficacy and safety of lidocaine hydrochloride jelly for the treatment of pain caused by breast cancer metastases to the skin]. Gan To Kagaku Ryoho 2012; 39:2063-2065. [PMID: 23267977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Breast cancer metastases to the skin significantly decrease quality of life(QOL) due to bleeding or dull pain. However, an effective treatment has not yet been established. In this study, we achieved an effective result by using lidocaine hydrochloride jelly[Xylocaine jelly(XJ)] when patients complained of temporarily increased dull pain. For the pain treatment for 5 women who developed the skin metastases of breast cancer after mastectomy, non-steroid anti-inflammatory drugs (NSAIDs) were used. In cases with defective control, both NSAIDs and opioids were used. However, it was difficult to control temporarily increased dull pain. Therefore, we applied 5 g XJ to the area of recurrence when the patients complained of increasing dull pain. This treatment rapidly reduced the pain and it was possible to reduce the use of analgesics and reduce side effects. After 5 g XJ was applied to the patients, their level of lidocaine in blood was reduced to within the safe zone, and no undesirable effects were observed. Treatment with XJ was easy to perform and was safe for the control of dull pain due to skin metastases of breast cancer. In conclusion, we believe that treatment with XJ is effective for dull pain.
Collapse
Affiliation(s)
- Mina Waraya
- Dept. of Surgery, Kitasato University School of Medicine, Japan
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Hayashi K, Kosaka Y, Sengoku N, Enomoto T, Kajita S, Kuranami M, Watanabe M. [Improvised surgical technique for elderly women with advanced breast cancer accompanied by extensive skin invasion]. Gan To Kagaku Ryoho 2012; 39:1938-1941. [PMID: 23267936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Patient 1 was a 63-year-old woman whose chief complaint was a mass in the left breast. Physical examination revealed an inverted left nipple, a very large mass on the anterior aspect of the sternum, and erythema. Because the tumor had directly invaded the sternum, T4cN3M0, stage IIIC breast cancer was diagnosed. The patient preoperatively received chemotherapy with 6 courses of FEC100 (5-fluorouracil, epirubicin, and cyclophosphamide) and 5 courses of nanoparticle albumin -bound paclitaxel (260 mg/m2), which enabled a partial response. Patient 2 was an 83-year-old woman whose chief complaint was a mass in the upper internal and external quadrants of the right breast measuring 20×15 cm and erythema. The mass was accompanied by enlarged right axillary lymph nodes(T4bN1M0, stage IIIB breast cancer). Both patients underwent core needle biopsy of the skin and breast masses. They were both diagnosed with invasive, lobular, triple-negative breast cancer (estrogen receptor negative, progesterone receptor negative, human epidermal growth factor receptor 2 negative). The surgical resection line was drawn to include the extensive skin invasion, and mastectomy and axillary dissection were performed. Skin grafting was scheduled but the retromammary space on the healthy side was dissected to the anterior border of the latissimus dorsi muscle, and the skin of the healthy side was used to cover the defect on the affected side. Consequently, the pendulous breast on the healthy side was elevated. This surgical technique provided an excellent aesthetic outcome without any skin problems, because autologous skin was used to fill the defect. Radiotherapy could subsequently be administered as scheduled. This procedure may be useful for elderly patients.
Collapse
Affiliation(s)
- Keiko Hayashi
- Dept. of Surgery, Social Insurance Sagamino Hospital, Japan
| | | | | | | | | | | | | |
Collapse
|
14
|
Kosaka Y, Kataoka A, Yamaguchi H, Ueo H, Akiyoshi S, Sengoku N, Kuranami M, Ohno S, Watanabe M, Mimori K, Mori M. Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer. Breast Cancer Res 2012; 14:R140. [PMID: 23113927 PMCID: PMC4053119 DOI: 10.1186/bcr3345] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Accepted: 09/03/2012] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Identification of useful markers associated with poor prognosis in breast cancer patients is critically needed. We previously showed that expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful to predict distant metastasis in gastric cancer patients. However, expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood of breast cancer patients has not yet been studied. METHODS Real-time reverse transcriptase-PCR was used to analyze vascular endothelial growth factor receptor-1 mRNA expression status with respect to various clinical parameters in 515 patients with breast cancer and 25 controls. RESULTS Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood was higher in breast cancer patients than in controls. Increased vascular endothelial growth factor receptor-1 mRNA expression was associated with large tumor size, lymph node metastasis and clinical stage. Patients with high vascular endothelial growth factor receptor-1 mRNA expression also experienced a poorer survival rate than those with low expression levels, including those patients with triple-negative type and luminal-HER2(-) type disease. CONCLUSIONS Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful for prediction of poor prognosis in breast cancer, especially in patients with triple-negative type and luminal-HER2(-) type disease.
Collapse
|
15
|
Ando-Tanabe N, Iwamitsu Y, Kuranami M, Okazaki S, Yasuda H, Nakatani Y, Yamamoto K, Watanabe M, Miyaoka H. Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls. Breast Cancer 2012; 21:453-62. [DOI: 10.1007/s12282-012-0405-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2012] [Accepted: 08/17/2012] [Indexed: 01/03/2023]
|
16
|
Inaji H, Iwata H, Nakayama T, Yamamoto N, Sato Y, Tokuda Y, Aogi K, Saji S, Watanabe K, Saito T, Yoshida M, Sato N, Saeki T, Takatsuka Y, Kuranami M, Yamashita H, Kikuchi A, Tabei T, Ikeda T, Noguchi S. Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer. Cancer Sci 2012; 103:1708-13. [PMID: 22676245 DOI: 10.1111/j.1349-7006.2012.02354.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2012] [Revised: 05/24/2012] [Accepted: 05/25/2012] [Indexed: 12/01/2022] Open
Abstract
This randomized phase II study was intended to identify the optimal dose of TAS-108, a novel steroidal antiestrogen, for the treatment of breast cancer in postmenopausal Japanese women. The potential clinical effects of TAS-108 on the uterus, bone, serum lipids, and hormones were also investigated. Postmenopausal women with hormone receptor-positive metastatic breast cancer who had previously received one or two endocrine therapies were randomly assigned to one of the three possible dose levels of TAS-108 (40, 80 or 120 mg/day). Oral TAS-108 was given daily, and the efficacy and safety of the three doses were evaluated. A total of 97 patients (33, 32, and 32 in the 40-, 80-, and 120-mg groups, respectively) were treated with TAS-108. The clinical benefit rate was 30.3% for the 40-mg, 25.0% for the 80-mg, and 25.0% for the 120-mg group. The 40-mg group achieved the prespecified target threshold. TAS-108 at all dose levels was well tolerated and appeared to have no harmful effects in terms of the variables examined in this study. We conclude that the optimal dose of TAS-108 among the three doses is 40 mg, once daily, for further studies. JAPIC Clinical Trials Information number: Japic CTI - 121754.
Collapse
Affiliation(s)
- Hideo Inaji
- Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 2012; 20:3355-64. [PMID: 22584733 DOI: 10.1007/s00520-012-1492-x] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2011] [Accepted: 04/30/2012] [Indexed: 12/22/2022]
Abstract
PURPOSE To elucidate whether adjuvant taxane monotherapy is a feasible and tolerable for postoperative breast cancer patients, we evaluated the severity of chemotherapy-induced peripheral neuropathy (CIPN) and the relative tolerability of regimens by health-related quality of life (HRQOL) assessment in node-positive breast cancer patients treated with taxane-containing regimens. METHODS We evaluated CIPN and HRQOL in the first 300 patients enrolled in a larger (1,060 total) multicenter phase III trial randomized to one of four adjuvant regimens: (1) anthracycline-cyclophosphamide followed by paclitaxel (ACP), (2) AC followed by docetaxel (ACD), (3) paclitaxel alone (PTX), or (4) docetaxel alone (DTX). CIPN was assessed by the Patient Neurotoxicity Questionnaire (PNQ) and the National Cancer Institute Common Toxicity Criteria, and HRQOL by Functional Assessment of Cancer Therapy-General (FACT-G). CIPN and HRQOL scores were compared between ACP and ACD vs. PTX and DTX, and ACP and PTX vs. ACD and DTX. RESULTS PNQ sensory scores were significantly higher in patients treated with taxane monotherapy compared to treatment with AC followed by taxane (P = .003). No significant differences in PNQ sensory scores were observed between the ACP and PTX vs. ACD and DTX regimens (P = .669). Regardless of taxane regimen, PNQ severity scores for CIPN appear to be largely reversible within 1 year of adjuvant treatment. No significant difference in FACT-G scores was observed between any regimens during the study treatments. CONCLUSIONS Patient-reported CIPN was significantly more severe with single-agent adjuvant taxane compared to AC followed by taxane treatment; however, the HRQOL findings support that single-agent taxane treatment is tolerable.
Collapse
Affiliation(s)
- Kojiro Shimozuma
- Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga 525-8577, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Ohsumi S, Shimozuma K, Ohashi Y, Takeuchi A, Suemasu K, Kuranami M, Ohno S, Watanabe T. Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02. Oncology 2012; 82:131-8. [PMID: 22433221 DOI: 10.1159/000336480] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2011] [Accepted: 01/03/2012] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To elucidate the time course of taxane-induced edema which may affect the patients' quality of life (QOL). PATIENTS AND METHODS Our study included the first 300 Japanese patients assigned to 1 of 4 regimens using docetaxel (DTX) or paclitaxel (PTX) by 1:1:1:1 in a randomized controlled trial to evaluate the efficacy of adjuvant therapies for node-positive breast cancer. Patients' QOL was prospectively assessed by the functional assessment of cancer therapy (FACT)-breast and -taxane (FACT-T) subscale. The scores of FACT items regarding edema and body weight were used as indicators of edema. RESULTS The scores for 'anasarca', 'edema of the hands' and 'edema of the legs and feet' of the FACT-T subscale worsened up to 1-2 months after chemotherapy, and body weights increased remarkably until cycle 8 in patients treated with DTX alone (75 mg/m(2), 8 cycles, every 3 weeks). Edema-related symptoms and body weight were relatively stable in the other treatment groups. There were statistically significant differences in the scores of those items and in the changes of body weight both between the DTX-alone group and the other three groups combined, and between the groups using DTX and those using PTX. CONCLUSION Many patients receiving DTX for >4 cycles suffered significantly from edema.
Collapse
Affiliation(s)
- Shozo Ohsumi
- Department of Breast Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata H, Mukai H, Uemura Y, Ohashi Y. PD07-02: Docetaxel Is Superior to Paclitaxel Given Every Three Weeks in Post Operative Patients with Node-Positive Breast Cancer: Results of the Final Analyses of the NSAS-BC (National Surgical Adjuvant Study of Breast Cancer) 02 Trial from Japan. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-pd07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Four cycles of doxorubicin plus cyclophosphamide (4-AC) followed by four cycles of a taxane is widely used for postoperative chemotherapy in breast cancer (BC). Concern about relatively rare, but life-threatening toxicity of anthracyclines such as heart failure and secondary leukemia has promoted research to seek anthracycline-free regimens. Since 1990's when taxanes were introduced, docetaxel (DTX) is used interchangeably with paclitaxel (PTX) for the treatment of BC, but they may differ more than initially anticipated. We conducted this trial to test two hypotheses: (1) Eight cycles of a taxane is not inferior to 4-AC followed by four cycles of a taxane; (2) one taxane is superior to the other.
Methods: Eligibility included a diagnosis of clinical stage I-IIIA and axillary node-positive BC, an age younger than 71 years and with performance status of 0 to 1. Patients were randomly assigned to receive either one of the following regimens;ACP: 4-AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 q3w x 4) followed by 4-PTX (175 mg/m2 q3w x 4)ACD: 4-AC followed by 4-DTX (75 mg/m2 q3w x 4)8-PTX: PTX (175 mg/m2 q3w x 8)8-DTX: DTX (75 mg/m2 q3w x 8)
Comparisons included PTX vs. DTX (ACP + 8-PTX vs. ACD + 8-DTX) and +AC vs. -AC (ACP + ACD vs. 8-PTX + 8-DTX). The primary endpoint was disease-free survival (DFS), and the secondary endpoints include overall survival (OS). The trial was powered to prove the non-inferiority of +AC to -AC (threshold hazard ratio 1.32) in terms of DFS. DFS was also compared between PTX and DTX to determine any superiority.
Results: A total of 1,060 eligible patients were accrued at 84 centers between December 2001 and April 2006. There were 348 DFS events and 166 deaths after a median followup of 72.2 months. DTX was superior to PTX in terms of both DFS (Hazard ratio(HR) 0.76; 95% Confidence Interval(CI) 0.62−0.95, p=0.012) and OS (HR 0.72;95%CI 0.53−0.97, p=0.033). -AC was not inferior to +AC with respect to DFS (HR: 1.21, 90% CI 1.01−1.44). Among the four arms, 8-PTX alone resulted in poorer DFS (compared with ACP, HR 1.42 95%CI 1.07−1.89).
Nausea and vomiting were more frequent with +AC than -AC. Edema and febrile neutropenia were more frequent with DTX than PTX. The incidence of sensory neuropathy was higher with PTX than DTX and it lasted for more than one year of the end of PTX treatment.
Conclusions: When AC, PTX and DTX were given every three weeks, both DFS and OS were better in the arms including DTX than in those including PTX. AC followed by a taxane can be replaced by 8-DTX.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD07-02.
Collapse
Affiliation(s)
- T Watanabe
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| | - M Kuranami
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| | - K Inoue
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| | - N Masuda
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| | - K Aogi
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| | - S Ohno
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| | - H Iwata
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| | - H Mukai
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| | - Y Uemura
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| | - Y Ohashi
- 1Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, Tokyo, Japan
| |
Collapse
|
20
|
Hayashi K, Kosaka Y, Sengoku N, Kondo Y, Enomoto T, Nishimiya H, Kajita S, Kuranami M, Watanabe M. [A rare case of huge triple-negative of accessory breast cancer enlarged during the course of chemotherapy]. Gan To Kagaku Ryoho 2011; 38:2071-2074. [PMID: 22202287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A 38-year-old premenopausal woman with a right axillary mass was told that she had an atheroma. The mass enlarged. An infectious atheroma was suspected, and incision and drainage were performed. A mass 4 cm in diameter was palpated in the right axillary region. Ultrasonography showed a mass 6 cm in diameter, and magnetic resonance imaging revealed a hypervascular mass at the same site. Stage IIIB triple-negative of accessory breast cancer (T4bN1M0) was diagnosed. The patient received four courses of FEC 100 (5-fluorouracil, epirubicin, and cyclophosphamide) as preoperative chemotherapy, but progressive disease was diagnosed, and the regimen was switched to weekly paclitaxel. The tumor became ulcerated and friable, and the hemoglobin level fell to 6 g/dL. Emergency surgery was thus performed. Postoperatively, the patient received six courses of chemotherapy with paclitaxel plus gemcitabine. Accessory breast cancer is extremely rare, but should be borne in mind when an axillary mass is encountered. In our patient, progressive disease had developed during the preoperative chemotherapy for accessory breast cancer. Although treatment was switched to a different regimen, bleeding was detected, and the patient underwent a semi-emergency surgery.
Collapse
|
21
|
Kondo Y, Nakakuma T, Kubo H, Futawatari N, Takahashi Y, Nishi Y, Yasokawa Y, Kosaka Y, Hayashi K, Sengoku N, Kuranami M. [A case of squamous cell cancer of the breast in which effective hemostasis was obtained by preoperative emergency radiation]. Gan To Kagaku Ryoho 2011; 38:2174-2176. [PMID: 22202320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A case was a 40-year-old woman. Her right breast was presented with massive bleeding ulcer and fixed with a pectoral muscle. Diagnosis of Stage IIIb breast cancer( T4b, N1, M0) showed a high inflammatory response and severe anemia. Palliative surgery was difficult because of hemostasis, and her general health also was in poor condition. The pathological diagnosis was squamous cell cancer. We underwent a total of 30 Gy radiation emergency hemostasisose. After radiation and chemotherapy, the lesion was undergone a radical surgery, and was reduced in size significantly. It was diagnosed as squamous cell cancer, which was more sensitive to general radiation so neoadjuvant chemoradiation therapy was effective.
Collapse
Affiliation(s)
- Yasushi Kondo
- Dept. of Surgery, Kitasato University Kitasato Institute Medical Center Hospital
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Shiroiwa T, Fukuda T, Shimozuma K, Kuranami M, Suemasu K, Ohashi Y, Watanabe T. Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial. Value Health 2011; 14:746-751. [PMID: 21839414 DOI: 10.1016/j.jval.2011.01.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2010] [Revised: 12/19/2010] [Accepted: 01/18/2011] [Indexed: 05/31/2023]
Abstract
OBJECTIVE To examine health-related quality of life, we investigated the effect of adjuvant chemotherapy regimens on utility scores assessed by the EuroQoL-5D (EQ-5D) instrument in a randomized, controlled trial for breast cancer patients after surgery. We also investigated the relationship between Functional Assessment of Cancer Therapy (FACT) scale scores and EQ-5D utilities. METHODS Patients were randomly assigned to the following four chemotherapy regimens: four cycles of anthracycline followed by paclitaxel (ACP), four cycles of anthracycline-containing regimens followed by docetaxel (ACD), eight cycles of paclitaxel (PTX), and eight cycles of docetaxel (DTX). Of 1060 registered, the first 300 consecutive patients were included in the current utility study. Utility scores were assessed using the EQ-5D instrument at baseline; cycles 3, 5, and 7; 7 months; and 1 year. We also evaluated the correlation between these scores and FACT-G, -B, and -Taxane scores at each time point. RESULTS Utility scores were significantly lower in the DTX group than in the ACP and ACD groups. Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time. The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane. Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores. CONCLUSIONS Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.
Collapse
Affiliation(s)
- Takeru Shiroiwa
- Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Shiga, Japan.
| | | | | | | | | | | | | |
Collapse
|
23
|
Hayashi K, Sengoku N, Kosaka Y, Enomoto T, Kajita S, Kondo Y, Kuranami M, Watanabe M. [A long-term survival case of progressive breast cancer detected in gastric metastasis]. Gan To Kagaku Ryoho 2010; 37:2756-2759. [PMID: 21224703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
A 51-year-old postmenopausal woman was diagnosed as having adenocarcinoma (gastric cancer type 4) from gastric biopsy by upper endoscopy. Her chief complaint was abdominal dilatation. Meanwhile, a breast CT suggested tumor in her left breast and was diagnosed as an invasive lobular carcinoma based on a core needle biopsy. After gastric biopsy, tissues are stained by ER and PgR in immunohistochemistry. The diagnosis was modified from gastric cancer to T2N1M1, stage IV left breast cancer, accompanied by a treatment. Chemotherapy with EC 6 course consisted of a weekly PTX 4 course (epirubicin, cyclophosphamide-weekly paclitaxel) was performed. After the chemotherapy, breast mass, ascites and tumor marker were dramatically improved. Then hormonal therapy was administered. She passed away 2 and 1/2 years after her first visit to the hospital. Metastatic gastric tumors simulating type 4 advanced gastric cancer (MGTS type 4) and invasive lobular carcinoma are known to have an unfavorable prognosis. There is no doubt, however, that the multidisciplinary treatments have brought a satisfaction to her and family. We should keep in mind a possibility of gastric metastasis of breast cancer, when consulting a female patient with gastric cancer type 4.
Collapse
|
24
|
Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuranami M, Gautam S, Hatabu H, Kan S, Mountford C. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 2010; 254:357-66. [PMID: 20093508 DOI: 10.1148/radiol.2542090405] [Citation(s) in RCA: 128] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To compare the capability of diffusion-weighted (DW) and contrast material-enhanced magnetic resonance (MR) imaging to provide diagnostic information on residual breast cancers following neoadjuvant chemotherapy and to assess apparent diffusion coefficients (ADCs) of the carcinoma prior to neoadjuvant chemotherapy to determine if the method could help predict response to chemotherapy. MATERIALS AND METHODS Institutional review board approval and informed consent were obtained. Three hundred ninety-eight patients underwent MR imaging of the breast, including DW MR (b values, 0 and 1500 sec/mm(2)) and contrast-enhanced MR imaging. Of these, the contralateral breast in 73 women was used as a control. Seventy-two patients with 73 lesions with malignant disease were treated by using neoadjuvant chemotherapy and were examined for residual disease following therapy. Three were excluded because of prolonged intervals between final MR imaging and surgery. Thus, 69 patients (70 lesions) with DW and contrast-enhanced MR imaging results were compared with postoperative histopathologic findings. The ADCs of the carcinoma prior to neoadjuvant chemotherapy were calculated for each patient, and those with complete response and residual disease were compared. RESULTS The accuracy for depicting residual tumor was 96% for DW MR imaging, compared with an accuracy of 89% for contrast-enhanced MR imaging (P = .06). There was no significant difference in prechemotherapy ADCs between pathologic complete response cases and those with residual disease. CONCLUSION DW MR imaging had at least as good of accuracy as did contrast-enhanced MR imaging for monitoring neoadjuvant chemotherapy. The ADCs prior to chemotherapy did not predict response to chemotherapy. The use of DW imaging to visualize residual breast cancer without the need for contrast medium could be advantageous in women with impaired renal function.
Collapse
Affiliation(s)
- Reiko Woodhams
- Department of Radiology, Kitasato University School of Medicine and Kitasato University Hospital, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ohsumi S, Shimozuma K, Ohashi Y, Takeuchi A, Nomura Y, Suemasu K, Kuranami M, Ohno S, Watanabe T. Objective and Subjective Assessment of Edema during Adjuvant Chemotherapy Using Taxane-Containing Regimens in a Randomized Controlled Trial: National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) 02. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-2090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Taxanes are frequently used in treatment of breast cancer (BC) patients. However, some patients treated with taxanes, especially docetaxel (DTX), experience severe edema during and following the treatment. We prospectively assessed body weight and health-related quality of life (HRQOL) related to edema in a randomized controlled trial (RCT) comparing four taxane-containing regimens in an adjuvant setting.Patients and Method: We conducted NSAS BC02 trial in which postoperative patients with node positive BC were randomly assigned to receive one of the following four adjuvant chemotherapeutic regimens; (1) ACP regimen: 4 cycles of doxorubicin 60mg/m2 plus cyclophosphamide 600mg/m2 q3weeks (AC) followed by 4 cycles of paclitaxel (PTX) 175 mg/m2 q3weeks, (2) ACD regimen: 4 cycles of AC followed by 4 cycles of DTX 75mg/m2 q3weeks, (3) PTX regimen: 8 cycles of PTX, (4) DTX regimen: 8 cycles of DTX. During the study we recorded body weight at baseline (at study entry), on day 1 of each cycle and at 8 months, and every 6 months thereafter. And we asked the patients to answer FACT-B, and -Taxane at baseline, on day 1 of cycle 3, 5, and 7, and at 8 and 12 months. We compared the change of weight and the scores of 4 items regarding edema in FACT-B (B8) (change in weight) and FACT-Taxane (Tax1 [anasarca], Tax2 [edema of hands], and Tax3 [edema of legs]) among the four regimens. Data were analyzed on an intent-to-treat basis. The statistical significance of the differences among the regimens was examined with analysis of covariance and t-test.Results: Of 1060 patients who entered N-SAS BC 02 trial, first 300 patients participated in this HRQOL study (ACP 74 patients, ACD 75, PTX 76, and DTX 75). The weight increased markedly and recovered by 8 months in the patients of DTX regimen, increased slightly in those of ACD regimen, and was almost stable in those of ACP and PTX regimens. The difference in the change of weight from the baseline to the 8th cycle between the patients of DTX plus ACD regimens and those of ACP plus PTX regimens was statistically significant (P< .0001). The compliance of FACT-B, and -Taxane was high throughout the study period (> 85 % at each point). The scores of B8, Tax1, Tax2, or Tax3 were relatively stable in ACP, ACD, and PTX regimens over the study period, but those of DTX regimen became lower (indicating worse HRQOL) up to 8 months, then recovered to the baseline except the scores of Tax2 which were still lower than those of other 3 regimens at 12 months. When the scores of the patients of DTX regimen were compared with those of other 3 regimens combined, the differences were statistically significant in all items of B8 (P= .0450), Tax1 (P= .0016), Tax2 (P< .0001), and Tax3 (P< .0001).Discussion: The patients who received 8 cycles of DTX were agonized by chemotherapy (CT)-related edema. However, the agony seemed to disappear by 6 months after the completion of CT except for that of edema of hands. The reason why only the scores of Tax2 did not recover at 12 months in the patients of DTX regimen is suspected to be the ipsilateral hand and arm edema affected by axillary dissection which might have lasted for a long time.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2090.
Collapse
Affiliation(s)
- S. Ohsumi
- 1NHO Shikoku Cancer Center, Ehime, Japan
| | | | | | | | - Y. Nomura
- 4Comprehensive Support Project for Oncological Research, Japan
| | | | | | - S. Ohno
- 7NHO Kyushu Cancer Center, Japan
| | | |
Collapse
|
26
|
Ueno S, Miyauchi K, Nakakuma T, Aramaki N, Iizuka M, Kurita A, Shiozawa K, Masuda Y, Nakano Y, Naruse M, Sengoku N, Kuranami M, Watanabe M. [Palliative home care for advanced and recurrence breast cancer--a six-case report]. Gan To Kagaku Ryoho 2009; 36 Suppl 1:78-80. [PMID: 20443409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Two years of palliative home care for advanced and recurrent breast cancer of six patients was performed since January 2007. The reasons to provide palliative home care include an administration of skin infiltrative tumor, pain, home oxygen therapy (HOT), and chemotherapy. Most important part of home palliative care is to prepare any physical and psychosocial problems among any types of occupation.
Collapse
|
27
|
Hayashi K, Sengoku N, Kosaka Y, Kondou Y, Sugiyama N, Enomoto T, Kuranami M, Watanabe M. [A successful case of advanced breast cancer of the elderly treated with the only breast-hormone therapy as PST]. Gan To Kagaku Ryoho 2009; 36:2480-2483. [PMID: 20037462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
An 83-year-old postmenopausal woman was referred to our hospital in order to get the treatment for ER positive advanced breast cancer (T4aN2M0, stage III b). The patient was diagnosed as the dissected aortic aneurysm and the hypertension. It was decided that an operation and chemotherapy would be too difficult with high existing risks. As a result, she was treated with anastrozole of PST, a 3rd-generation aromatase inhibitor, which led to the marked regression of the left breast cancer within a month. The cancer wasn't visualized after eighteen months. With the ongoing breast-hormone Therapy, no remote metastasis has been found after thirty months to this day. The patient hasn't experienced any adverse effects with the above-mentioned therapy. We concluded that the hormone (anastrozole) therapy as PST is a useful treatment for elderly postmenopausal woman with ER positive advanced breast cancer.
Collapse
|
28
|
Ueno S, Nakakuma T, Aramaki N, Shiozawa K, Iizuka M, Kurita A, Miyauchi K, Sengoku N, Kuranami M. [A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel]. Gan To Kagaku Ryoho 2009; 36:2471-2473. [PMID: 20037459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A 46-year-old woman was diagnosed with complaints of bilateral breast tumor with massive ascites retention. The patient was examined as scirrhous carcinoma by lacteal gland inspection and dysplastic cell by ascites cytotechnology. We diagnosed her case to be bilateral breast cancer with peritonitis carcinomatosa, lymph node metastases and bony metastases. In addition to that, gastric metastasis was diagnosed by the result of widespread irregular gastric mucosa, which was inspected through upper gastrointestinal endoscope. The patient was treated with S-1 and paclitaxel and has achieved a remarkable response. The patient's tumor, gastric metastasis, and ascites were disappeared almost completely.
Collapse
Affiliation(s)
- Soichiro Ueno
- Department of Surgery, Ageo Central General Hospital
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Iwata H, Mukai H, Tanaka S, Yamaguchi T, Ohashi Y. Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02 trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.516] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
516 Background: Anthracyclines are the key agents in postoperative regimens for breast cancer (BC). However, relatively rare but life threatening toxicity such as cardiac failure and secondary leukemia are the major concern with anthracycline containing regimens. Retrospective analyses suggested that anthracyclines can be excluded in some pts. Methods: Eligibility included node positive BC age less than 70 yo. Pts were randomized to receive either AC (doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2) every(q) 3 weeks(wks) x 4 -> P (paclitaxel) 175 mg/m2 q3 wks x 4 (ACP), the same AC -> D(docetaxel) 75 mg/m2 q3 wks x 4 (ACD), P 175 mg/m2 q3 wks x 8 (PTX) or D 75 mg/m2 q3 wks x 8(DTX). Comparison included P vs.D (ACP+PTX vs. ACD+DTX) and with AC or without AC (ACP+ACD vs. PTX+DTX). The primary endpoint was disease free survival (DFS) and the secondary endpoints included overall survival, adverse events (AE) and quality of life (QOL). The trial was powered to prove the non-inferiority of regimens without AC to those with AC (threshold hazard ratio [HR] 1.321) in terms of DFS. Results: 1,060 pts were accrued between Dec. 2000 and Mar.2006. 270 DFS events and 106 deaths after a median follow-up of 46.5 months were observed. In all randomised patients, 8 cycles taxane is not inferior to 4 cycles AC -> 4 cycles taxane in terms of DFS (HR:1.26, 95% CI; 0.99–1.60, p = 0.67). In the subset of HER-2 positive patients, 4 cycles AC -> 4 cycles taxane produced superior DFS to 8 cycles taxane (HR:1.63, 95% CI:1.05 - 2.54) but this is not observed in patients with HER-2 negative patients (HR:1.13, 95% CI: 0.85 - 1.50). D 75 mg/m2 tends to show superior DFS to P 175 mg/m2 (HR: 0.81, 95% CI; 0.64–1.03, p = 0.08). Nausea and vomiting was more frequent with AC -> a taxane than 8 cycles taxane. Edema and febrile neutropenia was more frequently observed with D 75 mg/m2 than P 175 mg/m2. The incidence of sensory neuropathy was higher with P 175 mg/m2 than D 75 mg/m2. Conclusions: AC improved DFS in the subset of pts with HER-2 overexpressing BC but not in non-selected population. DFS was better in the arms containing D than in the arms with P. Higher incidence of severe AEs was observed in the arms containing D than in arms with P. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Watanabe
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| | - M. Kuranami
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| | - K. Inoue
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| | - N. Masuda
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| | - K. Aogi
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| | - H. Iwata
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| | - H. Mukai
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| | - S. Tanaka
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| | - T. Yamaguchi
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| | - Y. Ohashi
- Hamamatsu Oncology Center, Hamamatsu, Japan; Kitasato University, Sagamihara, Japan; Saitama Cancer Center, Ina-machi, Japan; Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; Aichi Cancer Center, Nagoya, Japan; National Cancer Center East, Kashiwa, Japan; Kyoto University, Kyoto, Japan; University of Tokyo, Tokyo, Japan
| |
Collapse
|
30
|
Iizuka M, Sengoku N, Nakakuma T, Yoshimura N, Hayashi K, Enomoto T, Kuranami M, Watanabe M. [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. Gan To Kagaku Ryoho 2008; 35:2228-2230. [PMID: 19106579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
We here describe a case of advanced breast cancer (Stage IV) in which an oral S-1+TAM therapy following a primary systemic chemo-radiotherapy has been effective in maintaining the patient's QOL. A 40-year-old woman visited our hospital because of her left breast tumor. On physical examination, the tumor had invaded to the skin adjacent to the nipple forming a skin ulcer and marked deformity of the entire breast. Also noted were swollen lymph nodes in the left armpit. Subsequently, radiographic imaging tests revealed that the tumor had metastasized to the liver and lungs, as well as the skull. Accordingly, a primary systemic chemotherapy (4 series of AC/T) was started and followed by local radiation therapy (60 Gys) immediately after completing the chemotherapy. The metastasizing lesions in the liver, lungs, and skull had markedly reduced in the size and number, and the skin ulceration had healed up by these treatments. Afterwards, she has been given TAM daily and S-1 for 4 weeks with a 2-week interval. She has been quite well without any adverse effects by S-1 and TAM, and the primary as well as metastasizing lesions remain stable with normalized tumor marker levels (NC) for nearly 3 years.
Collapse
|
31
|
Niibe Y, Kuranami M, Matsunaga K, Takaya M, Kakita S, Hara T, Sekiguchi K, Watanabe M, Hayakawa K. Value of high-dose radiation therapy for isolated osseous metastasis in breast cancer in terms of oligo-recurrence. Anticancer Res 2008; 28:3929-3931. [PMID: 19192651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND For many years, patients with recurrent or distant metastatic cancer have been considered to be at the last stage of their lives because it was considered that the cancer had spread throughout the whole body. However, the development of methods for the early detection of recurrence or distant metastases allows the detection of limited site recurrence or single organ metastases, called oligometastases or oligo-recurrence. Additional local treatment for oligometastatic or oligo-recurrent lesions such as radiation therapy could be efficacious. The purpose of the current study was to evaluate radiation therapy for solitary osseous metastasis of breast cancer in terms of oligometastasis and oligo-recurrence. PATIENTS AND METHODS One hundred and thirteen breast cancer patients were treated with radiation therapy for osseous metastases at Kitasato University Hospital, Japan between January 1998 and March 2003. Out of them, seven patients had solitary osseous metastases with primary and other sites controlled. These patients were registered in the current study, three had lumber spine metastases, three pelvic and one thoracic spine. The median time between the initial treatment of the primary lesions and diagnosis of the osseous metastases was 44 months (range: 10-95 months). The median total radiation dose was 46 Gy (30-50 Gy; BED: biological effective dose, 39-60 Gy10). RESULTS The median follow-up time was 40 months (range: 11-80 months). All the patients were alive at the last follow-up. Only one patient relapsed in terms of pain from the osseous metastasis. This patient was treated with 30 Gy (BED 39 Gy10) irradiation, the lowest total dose among the seven patients. CONCLUSION Radiation therapy for solitary osseous metastasis might be efficacious and moreover, high dose could be useful for long-term pain relief of osseous metastasis.
Collapse
Affiliation(s)
- Yuzuru Niibe
- Department of Radiology, Kitasato University School of Medicine, 1-15-1, Kitasato, Sagamihrara, Kanagawa 228-8555, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Koshida Y, Kuranami M, Watanabe M. Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor. J Surg Res 2006; 134:270-7. [PMID: 16600304 DOI: 10.1016/j.jss.2006.02.025] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2005] [Revised: 12/27/2005] [Accepted: 02/15/2006] [Indexed: 02/07/2023]
Abstract
BACKGROUND Vascular endothelial growth factor (VEGF), a potent angiogenic factor, has been implicated in metastasis of colorectal cancer (CRC). The present study aimed to clarify whether cancer-stromal interaction induces the production of VEGF. MATERIALS AND METHODS Human colonic fibroblasts (CCD-18Co) and CRC (SW480, SW620) cells were analyzed in this study. The cell cycle of colonic fibroblasts during co-culture was analyzed by flow cytometry. VEGF and TGF-beta1 released into the conditioned media in co-culture models were measured. Northern blot with human specific VEGF probe was performed to identify the expression of VEGF in this model. RESULTS Co-culture of colonic fibroblasts with CRC cells increased the viability of fibroblasts during co-culture. Cell cycle analysis revealed that most of the fibroblasts co-cultured with CRC cells were arrested at G1 phase and few cells were in sub-G1 phase that indicates apoptosis. Although VEGF protein was detected in the culture media of all of the monocultures, co-cultivation of CRC with fibroblasts resulted in synergistic increase of VEGF production compared with monocultures. However TGF-beta1 protein was not detected in any conditioned medium. VEGF mRNA was detected in both CRC and fibroblasts. Under co-culture condition, an abundance of VEGF mRNA expression was noted in fibroblasts relative to CRC cells. CONCLUSIONS The present study suggests that CRC manipulates the host stroma to suppress apoptosis and up-regulate VEGF production.
Collapse
Affiliation(s)
- Yoshitomo Koshida
- Department of Surgery, Kitasato University School of Medicine, Kanagawa, Japan
| | | | | |
Collapse
|
33
|
Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuranami M, Watanabe M, Hayakawa K. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 2005; 29:644-9. [PMID: 16163035 DOI: 10.1097/01.rct.0000171913.74086.1b] [Citation(s) in RCA: 256] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The authors used breast diffusion-weighted imaging (DWI) to diagnose breast cancer and identify cancer extension. Isotropic DWI was performed with EPI. The apparent diffusion coefficient (ADC) value was calculated and displayed on an ADC map. The authors compared between the distribution of low ADC values and pathologic cancer extension. The mean ADC value of breast cancer was 1.12 +/- 0.24 x 10(-3) mm/s, which was lower than that of normal breast tissue. The ADC value for invasive ductal carcinoma was lower than that of noninvasive ductal carcinoma. The sensitivity of the ADC value for breast cancer using a threshold of less than 1.6 x 10(-3) mm/s was 95%. Seventy-five percent of all cases showed precise distribution of low ADC value as cancer extension. The causes of underestimation were susceptibility artifact from bleeding and the limit of spatial resolution. Benign proliferative change showed a low ADC value. The authors conclude that DWI has a potential for clinical appreciation in detecting breast cancer.
Collapse
Affiliation(s)
- Reiko Woodhams
- Department of Radiology, Kitasato University School of Medicine, Kanagawa, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Kuranami M, Kanai T, Hara H, Utsuki S, Miyazaki K, Masuda N, Bansho A, Kimura K. [Ambulatory chemotherapy in the Kitasato University Hospital]. Gan To Kagaku Ryoho 2005; 32:1494-5. [PMID: 16261696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
|
35
|
Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, Kuranami M, Watanabe M, Hayakawa K. ADC Mapping of Benign and Malignant Breast Tumors. Magn Reson Med Sci 2005; 4:35-42. [PMID: 16127252 DOI: 10.2463/mrms.4.35] [Citation(s) in RCA: 284] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
PURPOSE The purpose of this study was to investigate the utility of diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) value in differentiating benign and malignant breast lesions and evaluating the detection accuracy of the cancer extension. MATERIALS AND METHODS We used DWI to obtain images of 191 benign and malignant lesions (24 benign, 167 malignant) before surgical excision. The ADC values of the benign and malignant lesions were compared, as were the values of noninvasive ductal carcinoma (NIDC) and invasive ductal carcinoma (IDC). We also evaluated the ADC map, which represents the distribution of ADC values, and compared it with the cancer extension. RESULTS The mean ADC value of each type of lesion was as follows: malignant lesions, 1.22+/-0.31 x 10(-3) mm2/s; benign lesions, 1.67+/-0.54 x 10(-3) mm2/s; normal tissues, 2.09+/-0.27 x 10(-3) mm2/s. The mean ADC value of the malignant lesions was statistically lower than that of the benign lesions and normal breast tissues. The ADC value of IDC was statistically lower than that of NIDC. The sensitivity of the ADC value for malignant lesions with a threshold of less than 1.6 x 10(-3) mm2/s was 95% and the specificity was 46%. A full 75% of all malignant cases exhibited a near precise distribution of low ADC values on ADC maps to describe malignant lesions. The main causes of false negative and underestimation of cancer spread were susceptibility artifact because of bleeding and tumor structure. Major histologic types of false-positive lesions were intraductal papilloma and fibrocystic diseases. Fibrocystic diseases also resulted in overestimation of cancer extension. CONCLUSIONS DWI has the potential in clinical appreciation to detect malignant breast tumors and support the evaluation of tumor extension. However, the benign proliferative change remains to be studied as it mimics the malignant phenomenon on the ADC map.
Collapse
Affiliation(s)
- Reiko Woodhams
- Department of Radiology, Kitasato University School of Medicine, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Nozawa T, Enomoto T, Koshida Y, Sato Y, Kuranami M. Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer. Dis Colon Rectum 2004; 47:2093-100. [PMID: 15657660 DOI: 10.1007/s10350-004-0712-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
PURPOSE Platelet-derived endothelial cell growth factor, identified to be an angiogenic factor, has been implicated in metastases of colorectal cancer. This study aimed to clarify the role and localization of platelet-derived endothelial cell growth factor associated with human colorectal cancer invasion. METHODS Thirty-two patients with colorectal cancer who had undergone surgery were analyzed. Platelet-derived endothelial cell growth factor enzyme activities in the colorectal cancer specimens were measured. Cells that expressed platelet-derived endothelial cell growth factor were identified and localized by immunohistochemical analysis with anti-human platelet-derived endothelial cell growth factor antibody and by in situ hybridization with specific RNA probe. RESULTS Platelet-derived endothelial cell growth factor enzyme activity increased significantly in cancer tissues compared with normal colonic mucosa at various distances from the cancer. Immunohistochemical analysis and in situ hybridization demonstrated platelet-derived endothelial cell growth factor expression in stromal macrophages and fibroblasts located in cancer tissues and surrounding noncancerous tissues, although the tumor cells and normal colonic mucosa were negative. The value of platelet-derived endothelial cell growth factor expression was highest at the border of the colorectal cancer (35.3 +/- 8.9 percent), followed by the cancer nest (15.2 +/- 9.2 percent) and normal mucosa (7.7 +/- 3.4 percent). In the border area, the highest value of platelet-derived endothelial cell growth factor expression was observed in the submucosa (35.3 +/- 8.9 percent), followed by the muscular propria (21.9 +/- 7.7 percent) and the subserosa (14.9 +/- 5.5 percent). CONCLUSIONS Stromal macrophages and fibroblasts are responsible for elevated platelet-derived endothelial cell growth factor activity in colorectal cancer. The significance of enhanced expression of platelet-derived endothelial cell growth factor in the submucosa at the cancer border remains unclear. Cancer stroma may be an important factor for cancer angiogenesis and may serve as a treatment target through specific modulation of angiogenic factors.
Collapse
Affiliation(s)
- Tadashi Nozawa
- Department of Surgery, Kitasato University School of Medicine, Sagamihara, Japan
| | | | | | | | | |
Collapse
|
37
|
Sengoku N, Kuranami M, Handa K, Hayashi K, Enomoto T, Watanabe M. [A case of local advanced breast cancer with multiple lung metastases successfully treated with multimodal therapy]. Gan To Kagaku Ryoho 2004; 31:1927-9. [PMID: 15553762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
We report a case of local advanced breast cancer with multiple lung metastases (T4bN2M1) achieving a significant improvement of QOL by multimodal therapy with chemotherapy, antibody therapy, radiation therapy and surgery. The patient was a 47-year-old woman with mental deterioration who had an ulcerative breast cancer with multiple lung metastases. Breast biopsy led to a diagnosis of an invasive ductal carcinoma positive for erbB2 protein expression. She received 6 cycles of tri-weekly docetaxel (60 mg/m2) and weekly trastuzumab. Although metastases in the lung disappeared after chemotherapy, the response of breast ulceration was less satisfactory. Simple mastectomy followed by radiation therapy (50 Gy) to the axilla was performed as a palliative treatment. No signs of recurrence were observed for more than 14 months of treatment by trastuzumab. Multimodal therapy can improve patient QOL and the clinical outcomes in Stage IV local advanced breast cancer.
Collapse
|
38
|
Reigner B, Watanabe T, Schüller J, Lucraft H, Sasaki Y, Bridgewater J, Saeki T, McAleer J, Kuranami M, Poole C, Kimura M, Monkhouse J, Yorulmaz C, Weidekamm E, Grange S. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 2003; 52:193-201. [PMID: 12783206 DOI: 10.1007/s00280-003-0642-8] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2003] [Accepted: 04/11/2003] [Indexed: 10/26/2022]
Abstract
BACKGROUND Capecitabine (Xeloda) is a novel, oral fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue via a three-step enzymatic cascade. PURPOSE The objective of this study was to compare the pharmacokinetics of capecitabine and its metabolites in Japanese and Caucasian cancer patients. METHODS The study included 20 Japanese and 24 Caucasian patients with breast cancer. All patients received oral capecitabine 825 mg/m(2) twice daily for 14 days, except for study day 1 when only the morning dose was administered. On study days 1 and 14, blood and urine samples were collected after administration of the first dose and at steady state for the evaluation of the pharmacokinetics of capecitabine and its metabolites. The primary pharmacokinetic parameter was AUC(0-infinity ) of 5'-deoxy-5-fluorouridine (5'-DFUR) on day 14. The pharmacokinetic parameters in Japanese and Caucasian patients were compared using an ANOVA with calculation of the 90% confidence interval (CI) for the ratio of the geometric means. RESULTS Statistical analysis showed equivalence in the AUC of 5'-DFUR on day 14 with a ratio of 1.01 (90% CI 0.85-1.21). Similarly, no relevant influence of race on the pharmacokinetics of capecitabine, 5'-deoxy-5-fluorocytidine (5'-DFCR), or 5-FU was observed. Systemic exposure to alpha-fluoro-beta-alanine (FBAL) was higher in Caucasian than in Japanese patients. On study day 14, both the AUC and the maximum plasma concentration (C(max)) of FBAL were increased by 47% and 33% in Caucasian patients and Japanese patients, respectively. CONCLUSIONS No clinically relevant differences in the pharmacokinetics of capecitabine and its key metabolites 5'-DFUR, 5'-DFCR, and 5-FU were found between Japanese and Caucasian patients. Plasma concentrations of FBAL were higher in Caucasian than in Japanese patients but this difference is not clinically relevant as FBAL has no antiproliferative activity and systemic exposure to FBAL does not correlate with the tolerability of capecitabine.
Collapse
Affiliation(s)
- Bruno Reigner
- F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
Platelet-derived endothelial cell growth factor (PD-ECGF) has been identified to be an angiogenic factor, and a close relationship between the expression of PD-ECGF and tumor development has been postulated. This study was designed to assess both the role of PD-ECGF in human colorectal polyps as well as its relationship to the expression of other oncogenes during colorectal carcinogenesis. One hundred twenty patients with colon polyps who had undergone a polypectomy were studied. The polyps were classified based on the pathological findings as nonneoplastic or sporadic adenoma. The polyps were immunostained for PD-ECGF and vascular endothelial cell growth factor (VEGF), as well as for Ki-67 antigen and p53. The correlations between expression of PD-ECGF and clinicopathologic factors were examined. PD-ECGF was expressed at significant levels only in adenomas: in 4 of the 20 polyps with severe dysplasia (20%), and in 5 of the 20 cases of carcinoma in adenoma (25%). PD-ECGF was not detected in the nonneoplastic polyps and in adenomas with low-grade dysplasia. The intensity of immunostaining for PD-ECGF in adenomas correlated with the expression of Ki-67 antigen (P < 0.001) but not with that of p53. VEGF was not detected in any types of polyps. Angiogenic factors in colorectal adenomas might play an important role in carcinogenesis. The correlated expression of PD-ECGF and Ki-67 antigen suggests that PD-ECGF might not only act as an angiogenic factor, but also as a tumor growth factor.
Collapse
Affiliation(s)
- T Enomoto
- Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
| | | | | |
Collapse
|
40
|
Abstract
Protein kinase C (PKC), a serine/threonine kinase central to signal transduction, is implicated in tumor promotion. At present, 10 PKC isoforms have been cloned but their precise tissue-specific role has yet to be defined. In order to determine if PKC is reduced in colorectal cancers (CRC) and if specific PKC isoforms are altered in different stages of human CRC progression, total RNA was extracted from human primary CRC, liver metastases, paired normal mucosa, and liver as well as CRC cell lines and examined for specific PKC isoform mRNA expression. PKC-alpha, beta II, delta, epsilon, eta(L), theta, and zeta were expressed in all tissues examined, while PKC-beta I was not detected. PKC-alpha, beta II, delta, epsilon, and zeta were decreased in most primary CRC. However, the reduction in PKC-beta II was greatest in advanced primary CRC (P < 0.05). Although PKC-gamma was detected in about 29.6% of primary CRC and liver metastases, it was absent from all corresponding normal tissue. In addition, a second band hybridizing to our PKC-gamma probe was uniquely present only in cancerous tissue and not in brain control, suggestive of alternative splicing. PKC-alpha, delta, epsilon, and zeta were present in all cell lines. PKC-beta I/II were both uniformly absent from all cell lines. Since mRNA expression for most PKC isoforms is decreased in CRC, the previously reported decreases in overall PKC activity in CRC are not solely due to a post-translational enzyme modification.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- M Kuranami
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
| | | | | | | | | | | |
Collapse
|
41
|
Abstract
BACKGROUND Protein kinase C (PKC), centrally involved in signal transduction, has been implicated in colorectal carcinogenesis. The purpose of this study was to identify specific PKC isoform alterations associated with colorectal cancer metastases to the liver in an orthotopic transplantation nude mouse model. MATERIALS AND METHODS Solid subcutaneous tumors from colorectal cancer cell lines were established in dorsal sites of nude mice (3 mice per cell line) by subcutaneous injection of 10(7) cells (> 90% viable). Orthotopic transplantation cecal tumors, representative of each passage (S1-5) were examined for specific PKC isoform messenger ribonucleic acid (mRNA) expression. In addition, a cell line representative of passage S5 was established, characterized by light and electron microscopy, karyotype, clonogenicity, doubling time, and assayed for total PKC activity and PKC isoform mRNA expression. RESULTS After the fifth (S5) sequential orthotopic transplantation passage of the human colorectal cancer cell line, SW620, a highly metastatic clone was obtained. Relative to parental cells, metastatic SW620-S5 cells were less differentiated and demonstrated many more chromosomal abnormalities and lower clonogenicity. Total PKC activity was elevated in metastatic cells. In addition, specific PKC isoform mRNA alterations were noted: PKC-n (L) was abundantly expressed in the metastatic clone but absent from the parental cell line; PKC-alpha, delta and theta expression increased with serial orthotopic transplantation passages; PKC-delta remained unchanged, while PKC-beta was absent. CONCLUSIONS Metastases-specific PKC isoform alterations may serve as novel markers of metastases and treatment targets via specific PKC isoform modulation.
Collapse
Affiliation(s)
- M Kuranami
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
| | | | | |
Collapse
|
42
|
Kusuhara M, Yamaguchi K, Kuranami M, Suzaki A, Ishikawa S, Moon H, Adachi I, Hori S, Handa S. Stimulation of anchorage-independent cell growth by endothelin in NRK 49F cells. Cancer Res 1992; 52:3011-4. [PMID: 1317255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Endothelin (ET) is a vasoconstrictor peptide originally isolated from vascular endothelial cells. Recent studies have revealed that ET has many biological functions including growth factor-like activity. The present study aims to clarify whether ET-1 possesses the ability to stimulate anchorage-independent cellular growth, an indicator of factors with transforming activity. We found that NRK 49F cells possess a large number of high-affinity ET-1 receptors; labeled 125I-ET-1 binding was displaced by unlabeled ET-2 in a similar dose response, but in the case of ET-3, 100-fold more was required. Specific 125I-ET-3 binding was undetectable in NRK 49F cells, indicating that ET receptors in NRK 49F cells are ET-1/ET-2 selective. NRK 49F is a cell line which is most commonly used to assay for anchorage-independent cellular growth. Therefore, we explored whether ETs promote anchorage-independent cellular growth in this cell line. ET-1 and ET-2 stimulated NRK colony formation dose dependently in the presence of 1 nM epidermal growth factor (EGF). In contrast, ET-3 did not have colony-stimulating ability. In the presence of EGF, the maximal effect of ET-1 was approximately 90% of that of transforming growth factor-beta. Moreover, in the presence of maximal stimulating concentrations of EGF and transforming growth factor-beta, ET-1 additionally induced colony formation. These results indicate that ET-1 and -2 possess transforming growth factor-like activity for NRK 49F cells. Since ET-1 and -2 increased intracellular calcium levels, this ion may participate in signal transduction pathways by which ET-1 and -2 promote colony formation.
Collapse
Affiliation(s)
- M Kusuhara
- Growth Factor Division, National Cancer Center Research Institute, Tokyo, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Kuranami M, Yamaguchi K, Fuchigami M, Imanishi K, Watanabe T, Abe K, Asanuma F, Hiki Y. Effect of urine on clonal growth of human bladder cancer cell lines. Cancer Res 1991; 51:4631-5. [PMID: 1873808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Human urine contains growth factors; their physiological roles have not been established. The effect of normal human urine was examined in vitro on clonal growth of human bladder cancer cell lines. Clonal growth of HT-1376, HT-1197, and T24 was enhanced by five different fresh human urine samples from young men. Colony stimulating activity was detected in fractions with a molecular weight greater than 5000 by ultrafiltration. Sephadex G-50 gel chromatography identified two peaks of colony stimulative activity in HT-1376 with molecular weights of approximately 6000 and greater than 12,400, respectively; these two peaks also possessed immunoreactive epidermal growth factor (EGF) and NRK-49F transforming activities. The three bladder cancer cell lines possessed large quantities of EGF specific binding sites and exogenous EGF stimulated colony formation; EGF concentrations in human urine were found to be remarkably higher than those of exogenously added EGF which stimulated clonal growth of bladder cancer cell lines. Moreover, it was demonstrated that fresh urine samples (5%) incubated with anti-human EGF monoclonal antibody (KEM-10) neutralized completely the colony stimulating effects in HT-1376. These results indicate that fresh human urine stimulates clonal growth in human bladder cancer cell lines and that a major part of the activity is represented by urinary EGF. The data promote urinary EGF as a progressive agent of human bladder cancer.
Collapse
Affiliation(s)
- M Kuranami
- Growth Factor Division, National Cancer Center Research Institute, Tokyo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Watanabe T, Wu JZ, Morikawa K, Fuchigami M, Kuranami M, Adachi I, Yamaguchi K, Abe K. In vitro sensitivity test of breast cancer cells to hormonal agents in a radionucleotide-incorporation assay. Jpn J Cancer Res 1990; 81:536-43. [PMID: 2143180 PMCID: PMC5918064 DOI: 10.1111/j.1349-7006.1990.tb02603.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Breast cancer cell lines (MCF-7, T47D, BT-20 and STT-11) and fresh cells from malignant effusions of eight breast cancer patients were examined for their in vitro sensitivity to 17 beta-estradiol (E2), tamoxifen and toremifene in a miniaturized, improved nucleic acid precursor incorporation assay (MINI assay). Seven of the eight patients received either tamoxifen or toremifene following a MINI assay and the correlation was examined between in vitro sensitivity and clinical responses to the hormonal agents. In cell lines, E2 stimulated thymidine incorporation by estrogen receptor (ER)-rich cells, MCF-7 and T47D, but not by ER-poor cells, BT-20 and STT-11. Tamoxifen induced both ER-mediated and -unmediated effects in ER-rich cells. The latter effect was also observed in ER-poor cells. Toremifene had less ER-unmediated effect in all of the cells tested than tamoxifen did. The ER-mediated effect of toremifene was weaker than that of tamoxifen in cell lines but was equipotent to tamoxifen in fresh cells. E2 affected thymidine incorporation by cells withdrawn from patients who showed a partial response to the anti-estrogens. No clear correlation was demonstrated between in vitro sensitivity to anti-estrogens of fresh cells and clinical response to these agents. The present results suggest that 1) the MINI assay is a useful system to investigate hormonal effects on breast cancer cell lines; 2) clinical responses to anti-estrogens are not predicted by in vitro response to the agents but might be predicted by the in vitro response to E2; and 3) toremifene has a smaller non-specific effect on breast cancer cells than tamoxifen and is equipotent to tamoxifen in the ER-mediated effect in vitro.
Collapse
Affiliation(s)
- T Watanabe
- Department of Medicine, National Cancer Center Hospital, Tokyo
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Kuranami M, Yamaguchi K, Asanuma F, Suzuki M, Abe K. The growth promoting effect of transforming growth factor-alpha in human breast cancer cell lines. Jpn J Clin Oncol 1989; 19:360-6. [PMID: 2607638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Two human breast cancer cell lines, BT-20 and ZR-75-1, were examined with the aim of the elucidating the pathological roles of human transforming growth factor (TGF)-alpha in breast cancers. The TGF-alpha receptor was found to be present in both cell lines. A clonogenic assay revealed that concentrations of TGF-alpha greater than 10(10) M induced a significant increase in colony formation, indicating TGF-alpha to be a breast cancer cell growth factor. Northern blot analysis revealed, moreover, that both cell lines expressed TGF-alpha mRNA. Taking these observations together, it is reasonably possible to assume that TGF-alpha is an autocrine growth factor for breast cancer cells. Although it has been proposed that TGF-alpha could be an epidermal growth factor (EGF) superagonist with regard to its colony formation stimulating activity, the present study demonstrated the colony formation stimulating activities of TGF-alpha and EGF not to be all that much different in the two breast cancer cell lines.
Collapse
Affiliation(s)
- M Kuranami
- Growth Factor Division, National Cancer Center Research Institute, Tokyo
| | | | | | | | | |
Collapse
|
46
|
Imanishi K, Yamaguchi K, Kuranami M, Kyo E, Hozumi T, Abe K. Inhibition of growth of human lung adenocarcinoma cell lines by anti-transforming growth factor-alpha monoclonal antibody. J Natl Cancer Inst 1989; 81:220-3. [PMID: 2783462 DOI: 10.1093/jnci/81.3.220] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
We previously reported that two human lung adenocarcinoma cell lines (A-549 and PC-9) produce human transforming growth factor-alpha (hTGF-alpha) and express its receptors. In the present study an exogenously added monoclonal antibody against recombinant hTGF-alpha inhibited growth of these cell lines in vitro. This result indicated that endogenous hTGF-alpha produced by the cancer cells can function as an autocrine growth factor.
Collapse
Affiliation(s)
- K Imanishi
- Growth Factor Division, National Cancer Center Research Institute, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
47
|
Hiki Y, Shimao J, Yamao Y, Kobayashi N, Kuranami M, Kikuchi S, Atsumi S, Mieno H, Takahashi T, Sakakibara J. The concepts, procedures, and problems related in endoscopic laser therapy of early gastric cancer. A retrospective study on early gastric cancer. Surg Endosc 1989; 3:1-6. [PMID: 2711301 DOI: 10.1007/bf00591306] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
We report 34 cases of early gastric cancer in which endoscopic laser therapy was performed at the Kitasato University Hospital. The problems encountered were the size and location of the tumor, the presence of lymphatic metastasis or concomitant disorders, and technical problems associated with the irradiation procedure. Of the 34 cases, 22 cases were considered as completely cured (no malignancy was detected after laser therapy), 11 cases were incompletely cured (malignant cells were detected after laser therapy), and 1 case was undetermined.
Collapse
Affiliation(s)
- Y Hiki
- Department of Surgery, Kitasato University Hospital, Kanagawa, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|